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Sir,
Efalizumab (Raptiva®) is a recombinant humanized mono-
clonal IgG1 antibody that binds to CD11a, the α-subunit 
of leukocyte function antigen-1 (LFA-1). CD-11a 
modulates several key steps in the immunopathogenesis 
of psoriasis, including initial T-cell activation, trafficking 
from the circulation into psoriatic lesions, and reactiva-
tion therein (1). Efalizumab is approved in Europe and 
the USA for the treatment of plaque-type psoriasis, and 
several clinical trials have shown its safety and efficacy 
(2–4). The most common adverse events associated with 
efalizumab administration are acute flu-like symptoms 
(headache, chills, fever, myalgia, vomiting and nausea). 
More rarely, autoimmune thrombocytopaenia, urticaria, 
haemolytic anaemia or other blood abnormalities have 
been reported (4–6). 
CASE REPORT
We report here an uncommon adverse event associated 
with efalizumab in a 50-year-old Caucasian man 
who had had plaque-type psoriasis since the age of 35 
years. Stable plaque lesions were localized on the scalp, 
trunk, upper and lower extremities. The medical history 
included conventional topical therapies, cyclosporine, 
methotrexate and phototherapy. No medical or family 
history of allergies, atopic dermatitis or asthma were 
reported by the patient. The patient’s body weight was 
71 kg and height 170 cm. The severity of the psoriasis 
was moderate-to-severe, with a psoriasis area and seve-
rity index (PASI) score of 15. Joint involvement was not 
present. The patient began with efalizumab in February 
2007 at the standard loading dose of 0.7 mg/kg for the 
first week, and 1 mg/kg administered subcutaneously 
per week thereafter. Baseline laboratory data revealed a 
normal full blood count and all values were within the 
normal ranges, including the total IgE level. After one 
month of therapy, the patient presented an extensive 
urticarial rash accompanied by intense itching. Labo-
ratory tests revealed high levels of total IgE (> 2000 
IU/ml normal values 20.4–87.0). Anti-histamines were 
administered after complete radioallergosorbent test 
(RAST) and prick tests assessments. RAST and prick 
test results were negative, although these tests did not 
include efalizumab. The IgE level was persistently 
> 2000 IU/ml at the subsequent evaluations. The patient 
did not present any staphylococcal infection. Psoriasis 
did not improve significantly over the next 3 months. 
After 6 months of therapy efalizumab was discontinued 
due to the partial response (< 50% of PASI) and the 
IgE levels > 2000 IU/ml. After 2 weeks the IgE levels 
reduced to 1738 IU/ml and after 4 weeks there was a 
dramatic further reduction to 252 IU/ml (Fig. 1). In 
October 2007 the patient started a new treatment with 
the anti-tumour necrosis factor-α (TNF-α) receptor 
etanercept, at the conventional dosage of 50 mg twice 
weekly, administered subcutaneously for 12 weeks. 
A significant reduction in erythema, itch and desqua-
mation was observed after 4 weeks of therapy. After 
3 months, etanercept was administered at a dosage of 
25 mg twice weekly for 12 weeks, achieving an almost 
complete resolution of the psoriatic lesions (PASI 1.2). 
After 4 months of efalizumab discontinuation, the IgE 
level was 60 IU/ml.
DISCUSSION
By blocking the interaction of CD11a and the inter-
cellular adhesion molecule-1 (ICAM-1), efalizumab 
inhibits leukocyte trafficking into the skin as well as 
the continuous activation of T lymphocytes by antigen-
presenting cells in the dermis and epidermis (1, 7). 
Efalizumab has a relatively rapid onset of action, with 
significant improvements in mean PASI scores noted 
as early as week 4 (2). However, our patient did not 
achieve a significant clinical response (PASI 50) in 
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Fig. 1. An increased level of IgE was seen after efalizumab intake and a 
dramatic reduction in IgE with efalizumab discontinuation.
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mid-term treatment with efalizumab. Concomitantly 
with the efalizumab administration the patient had a 
persistent increase in IgE. The hyper-IgE was also as-
sociated with intense itch and urticarial rash, which was 
partially controlled by administration of anti-histamine. 
The hyper-IgE was observed at the beginning of spring. 
However, all the allergy tests performed during and 
after treatment were negative.
Urticaria associated with hyper-IgE induced by efa-
lizumab represents a rarely reported adverse reaction 
(6). Common adverse events during long-term treatment 
include increased cough, rhinitis, sinusitis and non-
 specific infections (e.g. colds) (3–4). 
Antibodies formed against efalizumab or other epi-
topes as a result of treatment with efalizumab, a mono-
clonal antibody with important roles in T-cell function, 
may be postulated as the mechanism of development 
of the high level of IgE in our patient. Drug-induced 
auto-antibodies may recognize combinatorial epitopes 
formed by drug binding to environmental antigens.  
Speculatively, the increase in IgE might represent an 
early parameter of unresponsiveness or partial response 
in a patient being treated with biologicals. 
Based on the Naranjo algorithm, this adverse reac-
tion was classed as possible (score = 8) (8). We believe 
that this combination is not coincidental, and that the 
development of hyper-IgE can be attributed to the 
medication. 
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